Want to join the conversation?
$BMY said CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naive Patients with Advanced Non-Small Cell Lung Cancer, failed to meet the primary endpoint of progression-free survival. The company will complete a full evaluation of the CheckMate -026 data and work with investigators on the future presentation of the results.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.